더바이오 11월 16일 주요뉴스

[https://www.thebionews.net/edit/webzine.html?idxno=684](https://www.thebionews.net/edit/webzine.html?idxno=684)

● “공모가, 프리 IPO 투자 단가 ‘하회’”…바이오 IPO ‘한파’에 기업·투자자 ‘한숨’
[https://www.thebionews.net/news/articleView.html?idxno=30259](https://www.thebionews.net/news/articleView.html?idxno=30259)

● EGFR 엑손20 변이 폐암 美 1차치료 각축…J&J·AZ·다이호, 항체·경구 3파전
[https://www.thebionews.net/news/articleView.html?idxno=30265](https://www.thebionews.net/news/articleView.html?idxno=30265)

● ‘리투오’로 외형·내실 키운 엘앤씨바이오…1447억 유증으로 생산 기반 확대
[https://www.thebionews.net/news/articleView.html?idxno=30264](https://www.thebionews.net/news/articleView.html?idxno=30264)

● 소아마취 전문의, AI 개발 왜? “고난도 수술 인력 부족, 조기경보로 안전 강화”
[https://www.thebionews.net/news/articleView.html?idxno=30257](https://www.thebionews.net/news/articleView.html?idxno=30257)

● “기존 약물 안 듣는 우울증 환자 3만명…‘스프라바토’ 급여로 새 치료 기회”
[https://www.thebionews.net/news/articleView.html?idxno=30292](https://www.thebionews.net/news/articleView.html?idxno=30292)

● “의사가 편해야 쓴다”…스튜디오키코, ‘AI 차팅’ 솔루션 의료 현장 본격 확장
[https://www.thebionews.net/news/articleView.html?idxno=30263](https://www.thebionews.net/news/articleView.html?idxno=30263)

● 휴온스, 비만 후보약 ‘HUC1-622’ 전임상서 3주간 체중 14.2% 감소
[https://www.thebionews.net/news/articleView.html?idxno=30304](https://www.thebionews.net/news/articleView.html?idxno=30304)

● 동아에스티, 비만 후보약 동물실험서 체중 최대 41.7%↓…릴리 신약과 유사
[https://www.thebionews.net/news/articleView.html?idxno=30294](https://www.thebionews.net/news/articleView.html?idxno=30294)

● 유한양행 비만신약, 생쥐 체중 22.9%↓…세마글루티드·오르포글리프론 상회
[https://www.thebionews.net/news/articleView.html?idxno=30290](https://www.thebionews.net/news/articleView.html?idxno=30290)

● 알테오젠, 비만신약 후보 동물실험서 릴리 ‘레타트루타이드’ 대비 반감기 4배
[https://www.thebionews.net/news/articleView.html?idxno=30267](https://www.thebionews.net/news/articleView.html?idxno=30267)

● 지아이이노베이션, 日 마루호서 ‘GI-301’ 기술료 46억원 수령
[https://www.thebionews.net/news/articleView.html?idxno=30287](https://www.thebionews.net/news/articleView.html?idxno=30287)

● HLB테라퓨틱스, ‘RGN-259’ 美 3상 톱라인서 1차 평가변수 유의성 미확보
[https://www.thebionews.net/news/articleView.html?idxno=30266](https://www.thebionews.net/news/articleView.html?idxno=30266)

● 보령, 셀트리온제약과 당뇨병 치료제 ‘네시나’·‘액토스’ 공동 판매한다
[https://www.thebionews.net/news/articleView.html?idxno=30308](https://www.thebionews.net/news/articleView.html?idxno=30308)

● 오스코텍, 1·2대주주에 합의 제안…“동등매각 보장 시 초다수결의제 폐지 찬성”
[https://www.thebionews.net/news/articleView.html?idxno=30298](https://www.thebionews.net/news/articleView.html?idxno=30298)

● “청약증거금만 11.4조원”…삼성바이오로직스, 2.7조원 자금 조달 성공 마무리
[https://www.thebionews.net/news/articleView.html?idxno=30270](https://www.thebionews.net/news/articleView.html?idxno=30270)

● 온코닉, 3Q 영업손실 43억원 적자전환…“R&D 투자 확대 영향”
[https://www.thebionews.net/news/articleView.html?idxno=30307](https://www.thebionews.net/news/articleView.html?idxno=30307)

● 中, 의료보험 약품 목록에 107개 추가…혁신신약 51개 역대 최대
[https://www.thebionews.net/news/articleView.html?idxno=30299](https://www.thebionews.net/news/articleView.html?idxno=30299)

● 대원제약, 국산 12호 신약 ‘펠루비’ 소아로 넓힌다…시럽제 2상 승인
[https://www.thebionews.net/news/articleView.html?idxno=30289](https://www.thebionews.net/news/articleView.html?idxno=30289)

● 지씨지놈, 6분기 연속 영업 흑자…3Q 영업익 직전 분기比 125%↑
[https://www.thebionews.net/news/articleView.html?idxno=30303](https://www.thebionews.net/news/articleView.html?idxno=30303)

● [카드뉴스] 더바이오 주간 ‘톱10’ 뉴스(11월 2주차)
[https://www.thebionews.net/news/articleView.html?idxno=30241](https://www.thebionews.net/news/articleView.html?idxno=30241)

● GI Innovation collects KRW 4.6 billion in technology fees from Japan's Maruho for ‘GI-301’
[https://www.thebionews.net/news/articleView.html?idxno=30312](https://www.thebionews.net/news/articleView.html?idxno=30312)

● Pediatric anesthesiologist builds AI – “Personnel shortage in high-difficulty surgeries met with early warning to enhance safety”
[https://www.thebionews.net/news/articleView.html?idxno=30311](https://www.thebionews.net/news/articleView.html?idxno=30311)

● Lunit CEO Brandon Beomseok Suh: “Overseas sales make up 95% – ‘Direct sales’ lay foundation for global growth”
[https://www.thebionews.net/news/articleView.html?idxno=30310](https://www.thebionews.net/news/articleView.html?idxno=30310)

● Greycoat Research Publishes 3,006-Cat Kidney Data Study in SCIE Journal
[https://www.thebionews.net/news/articleView.html?idxno=30278](https://www.thebionews.net/news/articleView.html?idxno=30278)

*제약바이오 11월 16일 아침 유튜브 라디오 뉴스(매일 아침 업로드)
[https://www.youtube.com/watch?v=dO9Ww1py2Jg](https://www.youtube.com/watch?v=dO9Ww1py2Jg)